Lv3
276 积分 2022-09-15 加入
The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study
23天前
已完结
The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study
23天前
已完结
Construct validity of a continuous metabolic syndrome score in children
24天前
已完结
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
1个月前
已完结
Crovalimab: First Approval
1个月前
已完结
Pegcetacoplan: First Approval
1个月前
已完结
Iptacopan: First Approval
1个月前
已完结
Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use
1个月前
已完结
Danicopan: First Approval
1个月前
已完结
我国群体性事件的典型特征、治理问题与对策建议
1年前
已采纳
小分子靶标的核糖开关生物传感器研究进展
1年前
已采纳
皖公网安备34019202002308
